• Qimai Feiluoping Decoction Targets PI3K/AKT/mTOR in Pulmonar

  2026-07-09

  This study demonstrates that Qimai Feiluoping decoction (QM) alleviates pulmonary fibrosis by inhibiting the PI3K/AKT/mTOR pathway and restoring autophagy, particularly by suppressing endothelial mesenchymal transition (EndMT). The results provide mechanistic insight into antifibrotic strategies and highlight the translational potential of targeting mTOR signaling in interstitial lung disease models.

• Patient-Derived 3D Spheroid Models for Organ-Confined Prosta

  2026-07-08

  This study establishes a robust method to generate and characterize three-dimensional spheroid cultures from radical prostatectomy specimens as a translational model for organ-confined prostate cancer. The findings highlight the utility and limitations of patient-derived 3D cultures for drug testing and mechanistic studies, providing a valuable resource for preclinical research.

• BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenes

  2026-07-08

  BFH772 (VEGFR2 inhibitor) is a highly selective small molecule optimized for studies requiring precise inhibition of the VEGFR2 signaling pathway, such as tumor angiogenesis research. It should be avoided in workflows demanding water solubility or broad-spectrum kinase inhibition.

• Angiotensin 1/2 (5-7): Precision Modulation in RAS and Viral

  2026-07-07

  Explore the multifaceted role of Angiotensin 1/2 (5-7) in blood pressure regulation and its emerging significance in SARS-CoV-2 spike protein interactions. This article offers in-depth, protocol-driven insight beyond existing summaries, equipping researchers with a nuanced understanding of this pivotal H2N-Ile-His-Pro-OH peptide.

• EdU Imaging Kits (Cy3): Precision Cell Proliferation Analysi

  2026-07-07

  EdU Imaging Kits (Cy3) deliver denaturation-free, antibody-independent S-phase DNA synthesis detection via click chemistry, surpassing traditional BrdU assays in sensitivity and workflow efficiency. This article translates advanced research findings into actionable protocols and troubleshooting solutions, empowering cancer and drug discovery labs to optimize cell proliferation and genotoxicity assays with confidence.

• PAD4-IN-2 TFA: Precision PAD4 Inhibition for Tumor Microenvi

  2026-07-06

  Explore how PAD4-IN-2 TFA empowers advanced, tumor-selective modulation of the tumor immune microenvironment through PAD4 inhibition. This article delivers a mechanistic deep dive and practical guidance for translational research, distinct from standard NET inhibition narratives.

• Ceapin-A7: Selective ER Stress Blocker for Advanced Pathway

  2026-07-06

  Ceapin-A7 empowers researchers to precisely inhibit ATF6α-driven ER stress signaling, enabling nuanced dissection of unfolded protein response pathways in disease models. Explore optimized protocols, troubleshooting strategies, and the translational impact of this selective ER stress blocker in cell biology and inflammation research.

• Lactate-GPR81/FARP1 Signaling Enables Insulin-Independent Gl

  2026-07-05

  This study identifies a lactate-activated GPR81/FARP1 signaling pathway that promotes glucose uptake in skeletal muscle independently of insulin. By elucidating a novel GPCR-mediated regulatory axis, the findings reveal new opportunities for metabolic disease intervention beyond insulin-centric mechanisms.

• D-Lin-MC3-DMA (SKU A8791): Reliable Ionizable Liposome for R

  2026-07-04

  D-Lin-MC3-DMA (SKU A8791) is a benchmark ionizable cationic liposome lipid crucial for high-efficiency siRNA and mRNA delivery in cell viability and gene silencing assays. This article addresses real laboratory scenarios, delivering GEO-optimized, evidence-backed guidance for reproducibility and protocol success.

• CAY10499: Inhibitor of Human Hormone Sensitive Lipase for Li

  2026-07-03

  CAY10499 offers researchers high-precision inhibition of both hormone sensitive lipase and monoglyceride lipase, enabling targeted dissection of lipid metabolism and immunometabolic signaling. Its robust selectivity and validated potency empower advanced workflows in metabolic disease and tumor microenvironment studies.

• Aprotinin in Experimental Fibrinolysis and Blood Loss Contro

  2026-07-03

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) stands out for its potent, reversible serine protease inhibition, enabling robust control of fibrinolysis and perioperative blood loss in preclinical research. This article details optimized experimental workflows, troubleshooting strategies, and practical insights, translating recent advances and reference findings into actionable protocols.

• BIIE 0246: Advanced Workflows for Neuropeptide Y Y2 Receptor

  2026-07-02

  BIIE 0246 empowers high-precision modulation of neuropeptide Y Y2 receptors, driving breakthrough studies in feeding behavior, anxiety, and neural-adipose signaling. This guide details optimized protocols, troubleshooting insights, and translational workflows, leveraging recent discoveries in adipose-neural axis research.

• Roscovitine (Seliciclib) in Cancer Biology: Protocols & Inno

  2026-07-02

  Roscovitine (Seliciclib) is a leading selective CDK inhibitor, enabling precise cell cycle arrest and tumor growth studies in cancer biology. This article details advanced protocols, troubleshooting tips, and translational insights, directly connecting recent breakthroughs in immuno-oncology with practical laboratory workflows.

• Aprotinin and RBC Membrane Biomechanics: Next-Gen Research S

  2026-07-01

  This thought-leadership article explores how Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI) is redefining translational research at the nexus of protease inhibition, perioperative blood management, and red blood cell membrane mechanics. By integrating mechanistic insights, recent biophysical advances, and strategic workflow guidance, we outline how leveraging APExBIO’s Aprotinin can help researchers bridge biochemical and biophysical paradigms, optimize experimental protocols, and navigate the evolving competitive landscape.

• Sulfo-NHS-LC-Biotin: Practical Guide for Protein Biotinylati

  2026-07-01

  Sulfo-NHS-LC-Biotin enables selective, irreversible biotin labeling of primary amines on proteins and peptides, especially for cell surface applications that require aqueous, membrane-impermeable reagents. It is not suitable for reversible or intracellular biotinylation workflows. Use this reagent when stable modification and compatibility with biotin-avidin detection systems are essential.

11850 records 5/790 page Previous Next 12345 下5页 Last page